Company / Capital Returned to Shareholders
West Pharmaceutical Services Capital Returned to Shareholders History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$195.2M
FY2025
5-year range
$128.2M / $620.0M
FY2021-FY2025
Trend
-68.5%
vs FY2024
Sector context
#52 of 108
Health Care
What the data says
At $195M, West Pharmaceutical Services's capital returned to shareholders ranks #52 of 108 in the Health Care sector. Capital Returned to Shareholders has fluctuated over the past 10 years, ranging from $29M in FY2016 to $620M in FY2024.
Based on SEC 10-K filings.
$195M in FY2025 with a 5-year CAGR of +11.6%.
Declined from $495M to $195M over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- +6.1%
- 5-Year CAGR
- +11.6%
- 10-Year CAGR
- -
Sector benchmark
-74.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.6%, indicating consistent growth.
- In FY2025, capital returned to shareholders decreased 68.5% year-over-year.
- Ranks #52 out of 108 companies in the Health Care sector.
- Peak capital returned to shareholders was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $195.2M | -68.5% |
| FY2024 | $620.0M | +25.2% |
| FY2023 | $495.3M | +202.8% |
| FY2022 | $163.6M | +27.6% |
| FY2021 | $128.2M | +13.6% |
| FY2020 | $112.9M | -11.9% |
| FY2019 | $128.2M | +13.6% |
| FY2018 | $112.9M | -0.5% |
| FY2017 | $113.5M | +290.0% |
| FY2016 | $29.1M | +9.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026